Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2025 · 10-Q
Revenue$188.00M$188.00M+29.4% vs Q2 2024 Net Income$11.98M$11.98M−38.9% vs Q2 2024 EPS Diluted$0.34$0.34−34.6% vs Q2 2024 Gross Profit$108,384,000+19.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$72,439,000+7.5% Free Cash Flowderived$72,374,000+7.8% Margins · derivedGross margin57.7%−4.9 pt vs Q2 2024
Operating margin18.7%−14.0 pt vs Q2 2024
Net margin6.4%−7.1 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end